v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended 18 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net income (loss) $ (15,386,729) $ (1,280,376) $ (13,966,367) $ 5,779,663  
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Stock-based compensation     212,791 161,710  
Depreciation and amortization     151,733 574,002  
Unrealized gain on short-term investment in equity securities 5,116,612 0 (1,361,070) 0  
Unrealized loss equity method investment at fair value 4,720,616 0 4,720,616 0  
Interest added to convertible note payable     0 35,265  
Loss (gain) on change in fair value of warrant liabilities (0) (726,000) 5,000 (8,506,000)  
Loss on debt extinguishment 0 125,242 0 125,242  
Changes in operating assets and liabilities:          
Accounts receivable, net     2,145,912 (903,472)  
Inventories, net     (209,359) (384,090)  
Prepaid expenses and other assets     (134,775) 454,235  
Accounts payable     (39,696) (1,657,616)  
Accrued expenses and other liabilities     106,818 335,852  
Contract liabilities     (4,354) (54,476)  
Net cash used in operating activities     (8,372,751) (4,039,685)  
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of property and equipment     (555,076) (23,882)  
Capitalization of internal use software costs     (57,833) 0  
Purchase of long-term equity securities     (10,000,000) 0  
Purchase of short-term investment in equity securities     (3,000,000) 0  
Net cash used in investing activities     (13,612,909) (23,882)  
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from the sale of Series G preferred stock     7,250,000 0  
Payment on accrued dividends     (904,634) 0  
Repayment on other short-term loans     0 (135,000)  
Issuance costs for sale of Series F preferred stock and warrants     (317,500) (47,000)  
Net cash provided by financing activities     7,937,202 5,945,746  
Effects of foreign exchange rates on cash flows     100,031 6,409  
Net change in cash     (13,948,427) 1,888,588  
Cash at beginning of period     29,858,655 3,613,996 $ 3,613,996
Cash at end of period 15,910,228 5,502,584 15,910,228 5,502,584 $ 15,910,228
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Interest cash paid     0 35,265  
Income taxes paid     0 0  
NON-CASH OPERATING AND FINANCING ACTIVITIES:          
Series F Warrants exchanged for shares of Common Stock     968 89  
Issuance of vested restricted Common Stock     0 79  
Amended Series B warrants reclassified to stockholders' equity     0 7,766,000  
Conversion of Promissory Note and accrued interest to shares of Common Stock   646,994 0 1,416,995  
Accrued dividends on Series F Preferred Stock 26,296 52,038 57,292 119,688  
Deemed dividends on Series F Preferred Stock, Series B and F Warrants and warrant exchange $ 39,276 3,677,811 1,388,759 4,734,143  
Accrued expense settled with Series B Warrant exercise     0 350,000  
Initial recognition of ROU asset and operating lease liabilities     2,008,598 0  
Conversion of Series F Preferred Stock into Common Stock [Member]          
NON-CASH OPERATING AND FINANCING ACTIVITIES:          
Conversion of stock     3,795 8,273  
Conversions of Series G Preferred Stock Into Common Stock [Member]          
NON-CASH OPERATING AND FINANCING ACTIVITIES:          
Conversion of stock     12,562 0  
COVID Loan [Member]          
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayments on COVID loans     (52,440) (162,770)  
Series F Preferred Stock and Warrants [Member]          
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from the sale of preferred stock and warrants     1,000,000 4,500,000  
Series B Warrants [Member]          
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from exercise of warrants     0 1,790,516  
NON-CASH OPERATING AND FINANCING ACTIVITIES:          
Amended Series B warrants reclassified to stockholders' equity   $ 7,766,000   7,766,000  
Accrued expense settled with Series B Warrant exercise       350,000  
Series F Warrants [Member]          
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from exercise of warrants     $ 961,776 $ 0